InMed Pharmaceuticals CEO holds 1.45M share options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. (INM) reports that President and Chief Executive Officer Gregory J. Divis directly holds options to purchase 1,454,398 common shares at an exercise price of $10.37 per share, expiring September 24, 2036. Effective November 6, 2026, the options were received in the merger in exchange for options in Pre-Merger Mentari.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) F1, F2 | -- | -- | -- |
Footnotes (2)
- F1. Effective as of November 6, 2026, (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").
- F2. Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Mentari held by the Reporting Person prior to the Merger. This option will vest as to 25% on July 20, 2027 and in equal monthly installments thereafter through July 20, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Key Terms
vest technical
wholly owned subsidiary technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many options does INM CEO Gregory J. Divis hold?
What is the vesting schedule for Gregory J. Divis’s INM options?
AI-generated analysis. How Rhea-AI works. Not financial advice.